AIM To explore the anti-tumor effects of esophageal cancerrelated gene 2(ECRG2) in combination with cisplatin(DDP) in DDP-resistant esophageal cancer cells(EC9706/DDP).METHODS A drug-resistant cell model was establish...AIM To explore the anti-tumor effects of esophageal cancerrelated gene 2(ECRG2) in combination with cisplatin(DDP) in DDP-resistant esophageal cancer cells(EC9706/DDP).METHODS A drug-resistant cell model was established, with EC9706/DDP cells being treated with ECRG2 and/or DDP. Cell viability was examined by MTT assay. The rate of cell apoptosis was determined by flow cytometry. The mR NA expression levels of proliferating cell nuclear antigen(PCNA), metallothionein(MT), and p53 were determined by RT-PCR and PCNA, while MT and p53 protein expression levels were determined by western blotting.RESULTS The anti-proliferative effect of ECRG2 in combination with DDP was superior when compared to ECRG2 or DDP alone. The inhibition rate for the combination reached its peak(51.33%) at 96 h. The early apoptotic rates of the control, ECRG2 alone, DDP alone, and ECRG2 plus DDP groups were 5.71% ± 0.27%, 12.68% ± 0.61%, 14.15% ± 0.87%, and 27.96% ±0.36%, respectively. Although all treatment groups were significantly different from the control group(P < 0.05), the combination treatment of ECRG2 plus DDP performed significantly better when compared to either ECRG2 or DDP alone(P < 0.05). The combination of ECRG2 and DDP significantly upregulated p53 m RNA and protein levels and downregulated PCNA m RNA and protein levels compared to ECRG2 or DDP alone(P < 0.05). However, no changes were seen in the expression of MT mR NA or protein.CONCLUSION ECRG2 in combination with DDP can inhibit viability and induce apoptosis in esophageal cancer DDP-resistant cells, possibly via upregulation of p53 expression and downregulation of PCNA expression. These findings suggest that the combination of ECRG2 and DDP may be a promising strategy for the clinical treatment of esophageal cancers that are resistant to DDP.展开更多
目的探讨人食管癌相关基因4(esophageal cancer related gene4,ECRG4)蛋白的亚细胞定位和重组ECRG4蛋白的体外抑癌功能。方法用激光扫描共聚焦显微镜成像法和Western blot方法检测ECRG4蛋白的定位;用MTT方法检测纯化的重组ECRG4蛋白的...目的探讨人食管癌相关基因4(esophageal cancer related gene4,ECRG4)蛋白的亚细胞定位和重组ECRG4蛋白的体外抑癌功能。方法用激光扫描共聚焦显微镜成像法和Western blot方法检测ECRG4蛋白的定位;用MTT方法检测纯化的重组ECRG4蛋白的体外抑癌功能。结果激光扫描共聚焦显微镜成像显示,内源性和外源性ECRG4蛋白主要定位在细胞质。Western blot方法在细胞无血清培养液中检测到ECRG4蛋白存在,提示ECRG4蛋白是分泌蛋白。纯化的重组ECRG4蛋白可以体外抑制EC9706细胞的增殖,抑制率随着ECRG4蛋白浓度增加而升高,成剂量-效应关系(P<0.05)。结论重组人ECRG4蛋白体外抑制肿瘤细胞增殖,可以作为ESCC的潜在治疗药物。展开更多
基金Supported by the Public Welfare Project Foundation of Henan Province,No.20130010
文摘AIM To explore the anti-tumor effects of esophageal cancerrelated gene 2(ECRG2) in combination with cisplatin(DDP) in DDP-resistant esophageal cancer cells(EC9706/DDP).METHODS A drug-resistant cell model was established, with EC9706/DDP cells being treated with ECRG2 and/or DDP. Cell viability was examined by MTT assay. The rate of cell apoptosis was determined by flow cytometry. The mR NA expression levels of proliferating cell nuclear antigen(PCNA), metallothionein(MT), and p53 were determined by RT-PCR and PCNA, while MT and p53 protein expression levels were determined by western blotting.RESULTS The anti-proliferative effect of ECRG2 in combination with DDP was superior when compared to ECRG2 or DDP alone. The inhibition rate for the combination reached its peak(51.33%) at 96 h. The early apoptotic rates of the control, ECRG2 alone, DDP alone, and ECRG2 plus DDP groups were 5.71% ± 0.27%, 12.68% ± 0.61%, 14.15% ± 0.87%, and 27.96% ±0.36%, respectively. Although all treatment groups were significantly different from the control group(P < 0.05), the combination treatment of ECRG2 plus DDP performed significantly better when compared to either ECRG2 or DDP alone(P < 0.05). The combination of ECRG2 and DDP significantly upregulated p53 m RNA and protein levels and downregulated PCNA m RNA and protein levels compared to ECRG2 or DDP alone(P < 0.05). However, no changes were seen in the expression of MT mR NA or protein.CONCLUSION ECRG2 in combination with DDP can inhibit viability and induce apoptosis in esophageal cancer DDP-resistant cells, possibly via upregulation of p53 expression and downregulation of PCNA expression. These findings suggest that the combination of ECRG2 and DDP may be a promising strategy for the clinical treatment of esophageal cancers that are resistant to DDP.
文摘目的探讨人食管癌相关基因4(esophageal cancer related gene4,ECRG4)蛋白的亚细胞定位和重组ECRG4蛋白的体外抑癌功能。方法用激光扫描共聚焦显微镜成像法和Western blot方法检测ECRG4蛋白的定位;用MTT方法检测纯化的重组ECRG4蛋白的体外抑癌功能。结果激光扫描共聚焦显微镜成像显示,内源性和外源性ECRG4蛋白主要定位在细胞质。Western blot方法在细胞无血清培养液中检测到ECRG4蛋白存在,提示ECRG4蛋白是分泌蛋白。纯化的重组ECRG4蛋白可以体外抑制EC9706细胞的增殖,抑制率随着ECRG4蛋白浓度增加而升高,成剂量-效应关系(P<0.05)。结论重组人ECRG4蛋白体外抑制肿瘤细胞增殖,可以作为ESCC的潜在治疗药物。
